Nature Communications (Mar 2022)

Ultrasound-controllable engineered bacteria for cancer immunotherapy

  • Mohamad H. Abedi,
  • Michael S. Yao,
  • David R. Mittelstein,
  • Avinoam Bar-Zion,
  • Margaret B. Swift,
  • Audrey Lee-Gosselin,
  • Pierina Barturen-Larrea,
  • Marjorie T. Buss,
  • Mikhail G. Shapiro

DOI
https://doi.org/10.1038/s41467-022-29065-2
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 11

Abstract

Read online

Synthetic biology has enabled the design of strategies for bacteria-based cancer immunotherapy. Here the authors report the development of focused ultrasound-activatable therapeutic bacteria engineered to express anti-CTLA-4 and anti-PD-L1 nanobodies for cancer immunotherapy.